- Home
- ABOS vs MRCC Comparison
ABOS vs MRCC Comparison
Compare ABOS & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABOS
- MRCC
- Stock Information
- Founded
- ABOS 1996
- MRCC 2011
- Country
- ABOS United States
- MRCC United States
- Employees
- ABOS N/A
- MRCC N/A
- Industry
- ABOS Biotechnology: Pharmaceutical Preparations
- MRCC Investment Managers
- Sector
- ABOS Health Care
- MRCC Finance
- Exchange
- ABOS Nasdaq
- MRCC Nasdaq
- Market Cap
- ABOS 166.4M
- MRCC 174.8M
- IPO Year
- ABOS 2021
- MRCC 2012
- Fundamental
- Price
- ABOS $2.52
- MRCC $8.05
- Analyst Decision
- ABOS Strong Buy
- MRCC Strong Buy
- Analyst Count
- ABOS 4
- MRCC 1
- Target Price
- ABOS $9.00
- MRCC $9.00
- AVG Volume (30 Days)
- ABOS 171.4K
- MRCC 42.9K
- Earning Date
- ABOS 08-13-2024
- MRCC 11-06-2024
- Dividend Yield
- ABOS N/A
- MRCC 12.39%
- EPS Growth
- ABOS N/A
- MRCC 194.63
- EPS
- ABOS N/A
- MRCC 0.36
- Revenue
- ABOS N/A
- MRCC $61,955,000.00
- Revenue This Year
- ABOS N/A
- MRCC N/A
- Revenue Next Year
- ABOS N/A
- MRCC N/A
- P/E Ratio
- ABOS N/A
- MRCC $22.41
- Revenue Growth
- ABOS N/A
- MRCC N/A
- 52 Week Low
- ABOS $1.81
- MRCC $6.69
- 52 Week High
- ABOS $5.65
- MRCC $8.14
- Technical
- Relative Strength Index (RSI)
- ABOS 46.11
- MRCC 62.48
- Support Level
- ABOS $2.15
- MRCC $7.96
- Resistance Level
- ABOS $2.55
- MRCC $8.14
- Average True Range (ATR)
- ABOS 0.16
- MRCC 0.11
- MACD
- ABOS -0.01
- MRCC 0.01
- Stochastic Oscillator
- ABOS 44.12
- MRCC 79.55
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.